Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesSLGL 54 3-Year EBITDA Growth Rate is 26.70% as of Mar. 2026, which is 245% above its 10-year median of 7.75. GuruFocus rates SLGL with a GF Score™ of 54/100 and a GF Value™ of $66.30 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,137 Biotechnology companies, Sol-Gel Technologies ranks better than 62.36% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sol-Gel Technologies was 26.70% per year. The lowest was -52.20% per year. And the median was 7.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sol-Gel Technologies 3-Year EBITDA Growth Rate Related Terms
SLGL vs AVXL, FATE, FHTX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.70% mean?
Sol-Gel Technologies (SLGL) has a 3-Year EBITDA Growth Rate of 26.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sol-Gel Technologies and its competitors. This is 245% above median its historical median of 7.75. According to the industry distribution chart, Sol-Gel Technologies ranks #428 out of 1137 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Sol-Gel Technologies' 3-Year EBITDA Growth Rate too high?
Sol-Gel Technologies' current 3-Year EBITDA Growth Rate of 26.70% is 245% above median its 10-year median of 7.75. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Sol-Gel Technologies' value of 26.70% is 79.2% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #428 out of 1137 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sol-Gel Technologies has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' 3-Year EBITDA Growth Rate compare to AVXL and FATE?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #428 out of 1137 companies for 3-Year EBITDA Growth Rate. This puts Sol-Gel Technologies in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Sol-Gel Technologies' value of 26.70% is 79.2% above this benchmark. While the company's 10-year median is 7.75 vs. the industry median of 14.90, Sol-Gel Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current 3-Year EBITDA Growth Rate of 26.70% is 79.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current 3-Year EBITDA Growth Rate is 26.70%, which is 245% above median its own 10-year median of 7.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $66.30, compared to a current price of $84.30 — trading 27.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.70%, which is 245% above median its 10-year median of 7.75 and 79.2% above the Biotechnology industry median of 14.90. Sol-Gel Technologies' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current 3-Year EBITDA Growth Rate is 26.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $84.30 is trading 27.1% above its estimated GF Value™ of $66.30.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
3-Year EBITDA Growth Rate: 26.70% (245% above median its 10-year median of 7.75)
GF Value™: $66.30 vs. price of $84.30 (27.1% above fair value)
Industry Position: 79.2% above the Biotechnology median (#428 of 1137)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
54GF Score
Get the complete analysis for SLGL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
